Literature DB >> 28371113

Simulated Sunlight-Mediated Photodynamic Therapy for Melanoma Skin Cancer by Titanium-Dioxide-Nanoparticle-Gold-Nanocluster-Graphene Heterogeneous Nanocomposites.

Yan Cheng1, Yun Chang1,2, Yanlin Feng1,2, Ning Liu1, Xiujuan Sun1, Yuqing Feng3, Xi Li3, Haiyuan Zhang1.   

Abstract

Simulated sunlight has promise as a light source able to alleviate the severe pain associated with patients during photodynamic therapy (PDT); however, low sunlight utilization efficiency of traditional photosensitizers dramatically limits its application. Titanium-dioxide-nanoparticle-gold-nanocluster-graphene (TAG) heterogeneous nanocomposites are designed to efficiently utilize simulated sunlight for melanoma skin cancer PDT. The narrow band gap in gold nanoclusters (Au NCs), and staggered energy bands between Au NCs, titanium dioxide nanoparticles (TiO2 NPs), and graphene can result in efficient utilization of simulated sunlight and separation of electron-hole pairs, facilitating the production of abundant hydroxyl and superoxide radicals. Under irradiation of simulated sunlight, TAG nanocomposites can trigger a series of toxicological responses in mouse B16F1 melanoma cells, such as intracellular reactive oxygen species production, glutathione depletion, heme oxygenase-1 expression, and mitochondrial dysfunctions, resulting in severe cell death. Furthermore, intravenous or intratumoral administration of biocompatible TAG nanocomposites in B16F1-tumor-xenograft-bearing mice can significantly inhibit tumor growth and cause severe pathological tumor tissue changes. All of these results demonstrate prominent simulated sunlight-mediated PDT effects.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  melanoma; nanocomposites; photodynamic therapy; simulated sunlight; titanium dioxide

Mesh:

Substances:

Year:  2017        PMID: 28371113     DOI: 10.1002/smll.201603935

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  7 in total

Review 1.  Melanoma treatment: from conventional to nanotechnology.

Authors:  Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

2.  RGD-modified dihydrolipoamide dehydrogenase conjugated to titanium dioxide nanoparticles - switchable integrin-targeted photodynamic treatment of melanoma cells.

Authors:  Avraham Dayan; Gideon Fleminger; Osnat Ashur-Fabian
Journal:  RSC Adv       Date:  2018-03-01       Impact factor: 4.036

3.  Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.

Authors:  Yong Tao; Yunsheng Ou; Hang Yin; Yanyang Chen; Shenxi Zhong; Yongjian Gao; Zenghui Zhao; Bin He; Qiu Huang; Qianxing Deng
Journal:  Int J Oncol       Date:  2017-09-27       Impact factor: 5.650

Review 4.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

Review 5.  Photo/electrocatalysis and photosensitization using metal nanoclusters for green energy and medical applications.

Authors:  Tokuhisa Kawawaki; Yuichi Negishi; Hideya Kawasaki
Journal:  Nanoscale Adv       Date:  2019-10-18

Review 6.  Gold nanoclusters: Photophysical properties and photocatalytic applications.

Authors:  Dajiao Cheng; Rong Liu; Ke Hu
Journal:  Front Chem       Date:  2022-07-19       Impact factor: 5.545

7.  Induction of Immunogenic Cell Death by Photodynamic Therapy Mediated by Aluminum-Phthalocyanine in Nanoemulsion.

Authors:  Mosar Corrêa Rodrigues; Wellington Tavares de Sousa Júnior; Thayná Mundim; Camilla Lepesqueur Costa Vale; Jaqueline Vaz de Oliveira; Rayane Ganassin; Thyago José Arruda Pacheco; José Athayde Vasconcelos Morais; João Paulo Figueiró Longo; Ricardo Bentes Azevedo; Luis Alexandre Muehlmann
Journal:  Pharmaceutics       Date:  2022-01-14       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.